P.A.W. Capital Corp reduced its stake in Gilead Sciences, Inc. (NASDAQ:GILD) by 50.0% in the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 15,000 shares of the biopharmaceutical company’s stock after selling 15,000 shares during the period. P.A.W. Capital Corp’s holdings in Gilead Sciences were worth $1,215,000 at the end of the most recent reporting period.
Other hedge funds also recently added to or reduced their stakes in the company. GHP Investment Advisors Inc. increased its stake in shares of Gilead Sciences by 19.3% during the first quarter. GHP Investment Advisors Inc. now owns 3,499 shares of the biopharmaceutical company’s stock valued at $238,000 after purchasing an additional 567 shares in the last quarter. Airain ltd increased its stake in shares of Gilead Sciences by 38.1% during the first quarter. Airain ltd now owns 402,196 shares of the biopharmaceutical company’s stock valued at $27,317,000 after purchasing an additional 110,923 shares in the last quarter. Family Legacy Inc. bought a new position in shares of Gilead Sciences during the first quarter valued at approximately $360,000. Northwestern Mutual Investment Management Company LLC increased its stake in shares of Gilead Sciences by 74.6% during the first quarter. Northwestern Mutual Investment Management Company LLC now owns 264,214 shares of the biopharmaceutical company’s stock valued at $17,945,000 after purchasing an additional 112,932 shares in the last quarter. Finally, BP PLC increased its stake in shares of Gilead Sciences by 13.2% during the first quarter. BP PLC now owns 163,000 shares of the biopharmaceutical company’s stock valued at $11,069,000 after purchasing an additional 19,000 shares in the last quarter. 75.94% of the stock is owned by institutional investors.
In related news, insider John C. Martin sold 73,333 shares of the firm’s stock in a transaction that occurred on Monday, October 2nd. The shares were sold at an average price of $82.56, for a total value of $6,054,372.48. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, EVP Gregg H. Alton sold 25,000 shares of the firm’s stock in a transaction that occurred on Monday, October 2nd. The stock was sold at an average price of $82.65, for a total transaction of $2,066,250.00. The disclosure for this sale can be found here. Insiders sold 494,999 shares of company stock worth $37,404,139 in the last 90 days. 1.30% of the stock is currently owned by corporate insiders.
Gilead Sciences (NASDAQ:GILD) last issued its earnings results on Thursday, October 26th. The biopharmaceutical company reported $2.27 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $2.13 by $0.14. Gilead Sciences had a net margin of 42.22% and a return on equity of 57.15%. The company had revenue of $6.51 billion for the quarter, compared to analysts’ expectations of $6.40 billion. During the same quarter last year, the company posted $2.75 earnings per share. The firm’s quarterly revenue was down 13.2% on a year-over-year basis. analysts expect that Gilead Sciences, Inc. will post 8.53 EPS for the current fiscal year.
The business also recently announced a quarterly dividend, which will be paid on Thursday, December 28th. Investors of record on Friday, December 15th will be issued a $0.52 dividend. This represents a $2.08 annualized dividend and a yield of 2.85%. The ex-dividend date is Thursday, December 14th. Gilead Sciences’s dividend payout ratio is currently 23.66%.
GILD has been the subject of a number of analyst reports. Argus raised shares of Gilead Sciences from a “hold” rating to a “buy” rating and set a $100.00 target price for the company in a research note on Thursday, August 31st. Deutsche Bank reaffirmed a “buy” rating and set a $81.00 target price on shares of Gilead Sciences in a research note on Thursday, August 31st. Vetr raised shares of Gilead Sciences from a “buy” rating to a “strong-buy” rating and set a $91.98 target price for the company in a research note on Friday, October 13th. Credit Suisse Group reissued an “outperform” rating and set a $85.00 price target (up previously from $79.00) on shares of Gilead Sciences in a research report on Tuesday, August 29th. Finally, Maxim Group reissued a “hold” rating on shares of Gilead Sciences in a research report on Monday, August 28th. One research analyst has rated the stock with a sell rating, thirteen have issued a hold rating, seventeen have assigned a buy rating and one has given a strong buy rating to the company. Gilead Sciences currently has a consensus rating of “Buy” and an average price target of $85.03.
ILLEGAL ACTIVITY WARNING: This article was first published by Community Financial News and is the sole property of of Community Financial News. If you are viewing this article on another domain, it was stolen and reposted in violation of United States & international copyright and trademark law. The original version of this article can be read at https://www.com-unik.info/2017/12/22/p-a-w-capital-corp-decreases-position-in-gilead-sciences-inc-gild.html.
Gilead Sciences Profile
Gilead Sciences, Inc is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need. The Company’s portfolio of products and pipeline of investigational drugs includes treatments for Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS), liver diseases, cancer, inflammatory and respiratory diseases and cardiovascular conditions.
Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.